Patients with neurologic disorders such as spinal cord injury, spina bifida and multiple sclerosis may suffer from neurogenic detrusor overactivity (NDO) or low bladder compliance
. The majority of these patients encounter symptoms of discomfort, urgency, frequency with or without incontinence that can be very bothersome on a daily basis.
Neurogenic detrusor overactivity is a type of voiding disorder, accompanied by decreased bladder capacity, increased intravesical pressure, and reduced bladder compliance
with or without incontinence.
In this study, detrusor activity, bladder sensation, bladder capacity, bladder compliance
, urethral function, maximum bladder capacity, Pves max (maximum intravesical pressure), Pabd max (maximum abdominal pressure), and Pdet max (maximum detrusor pressure) were recorded in the filling phase.
Work of Erol B, et al and others showed that normal compliance and DA can be found in patients with supra-sacral injuries as DO and normal bladder compliance
can be seen with sacral injuries14,15.
Urodynamic tests may report detrusor hyperreflexia either sporadically or combined with impaired contractility, decreased bladder compliance
or capacity, bladder hypersensitivity, hypoor acontractile bladder and increased postvoid residual urine concomitant to the detrusor hyperreflexia (3, 5- 8, 10).
refers to the distendibility of the bladder wall.
The simplest urodynamic method to determine whether obstructive uropathy (BPH) is serious enough to demand treatment is the measurement of bladder compliance
. The incidence of altered bladder compliance
in a population with BPH diagnosed by symptoms and flow rates is unknown but it must be low.
Regarding urodynamic study, patients achieved significant increase in bladder capacity with mean 342.1 [+ or -] 68.3 ml (p = .0001), decrease in end filling pressure 28.1 [+ or -] 6.9 cm [H.sub.2]O (p = .0001), and significant increase in bladder compliance
12.8 [+ or -] 3.9 ml/cm [H.sub.2]O (p = .0001) measured with formula: bladder compliance
In the lower urinary tract, Imatinib reduces both spontaneous and inducible bladder activity and it improves bladder compliance
, capacity, and voiding frequency during guinea-pig cystometry [15,17, 40].
Relapsing-remitting MS showed significant improvements in the OABSS, Qmax, and bladder volume at the first desire to voiding, maximum bladder volume and bladder compliance
after the treatment (P < 0.05).
decreased significantly at the 4-weektime point after BOO.